Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2017 1
2018 1
2019 1
2020 2
2021 3
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
Spikes LA, Bajwa AA, Burger CD, Desai SV, Eggert MS, El-Kersh KA, Fisher MR, Johri S, Joly JM, Mehta J, Palevsky HI, Ramani GV, Restrepo-Jaramillo R, Sahay S, Shah TG, Deng C, Miceli M, Smith P, Shapiro SM. Spikes LA, et al. Among authors: eggert ms. Pulm Circ. 2022 Apr 7;12(2):e12063. doi: 10.1002/pul2.12063. eCollection 2022 Apr. Pulm Circ. 2022. PMID: 35514770 Free PMC article.
Infiltrative lung disease due to noncytotoxic agents.
Lock BJ, Eggert M, Cooper JA Jr. Lock BJ, et al. Among authors: eggert m. Clin Chest Med. 2004 Mar;25(1):47-52. doi: 10.1016/S0272-5231(03)00129-1. Clin Chest Med. 2004. PMID: 15062596 Review.
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.
Rahaghi FF, Balasubramanian VP, Bourge RC, Burger CD, Chakinala MM, Eggert MS, Elwing JM, Feldman J, King C, Klinger JR, Mathai SC, McConnell JW, Palevsky HI, Restrepo-Jaramillo R, Safdar Z, Sager JS, Sood N, Sulica R, White RJ, Hill NS. Rahaghi FF, et al. Among authors: eggert ms. Pulm Circ. 2022 Apr 7;12(2):e12055. doi: 10.1002/pul2.12055. eCollection 2022 Apr. Pulm Circ. 2022. PMID: 35514769 Free PMC article.
Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.
Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N; PHAR Investigators. Min J, et al. Am J Respir Crit Care Med. 2021 Mar 15;203(6):761-764. doi: 10.1164/rccm.202010-3967LE. Am J Respir Crit Care Med. 2021. PMID: 33211974 Free PMC article. No abstract available.
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry.
DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ; PHAR Investigators. DuBrock HM, et al. Among authors: eggert m. Pulm Circ. 2022 Dec 15;12(4):e12172. doi: 10.1002/pul2.12172. eCollection 2022 Oct. Pulm Circ. 2022. PMID: 36540874 Free PMC article.
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V. Frost A, et al. Among authors: eggert m. J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12. J Heart Lung Transplant. 2019. PMID: 30391194 Free article. Clinical Trial.
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.
DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ. DuBrock HM, et al. Among authors: eggert m. Pulm Circ. 2021 May 17;11(3):20458940211020913. doi: 10.1177/20458940211020913. eCollection 2021 Jul-Sep. Pulm Circ. 2021. PMID: 34158918 Free PMC article.
Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR).
Minhas J, Narasimmal SP, M Bull T, Marco T, McConnell JW, Lammi MR, Thenappan T, P Feldman J, S Sager J, B Badesch D, Ryan JJ, C Grinnan D, Zwicke D, M Horn E, Elwing JM, Moss JE, Eggert M, Shlobin OA, P Frantz R, D Bartolome S, Mathai SC, Mazimba S, C Pugliese S, Al-Naamani N. Minhas J, et al. Among authors: eggert m. Pulm Circ. 2021 Oct 14;11(4):20458940211053196. doi: 10.1177/20458940211053196. eCollection 2021 Oct-Dec. Pulm Circ. 2021. PMID: 34671455 Free PMC article.
13 results